Immune checkpoint inhibitors (ICIs), particularly inhibitors of the programmed cell death 1 (PD‐1)/PD‐1 ligand (PD‐L1) axis, have altered the landscape of non‐small cell lung cancer (NSCLC) treatment.2 The gene discussed is PDCD1; the disease is lung cancer.